Blog
RSS FeedPosted by Michael Wonder on 31 Dec 2020
Tetra Bio-Pharma files new drug submission for Reduvo in Canada
30 December 2020 - The addressable market is estimated to be $80 million CDN by 2022. ...
Posted by Michael Wonder on 27 Dec 2020
Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics announce the filing of an application for Reeqonus (favipiravir) tablets for the treatment of COVID-19 under Health Canada’s Interim Order
22 December 2020 - Dr. Reddy’s Laboratories, Appili Therapeutics and Global Response Aid today announced that Dr. Reddy’s Canada has ...
Posted by Michael Wonder on 23 Dec 2020
Health Canada approves ALK's Ragwitek sublingual allergy immunotherapy tablets for paediatric patients with ragweed allergy
22 December 2020 - With the indication expanded to paediatric patients, ALK Canada now provides adults and children a SLIT tablet ...
Posted by Michael Wonder on 23 Dec 2020
Janssen announces Health Canada approval of Darzalex combination regimen for newly diagnosed, transplant eligible patients with multiple myeloma
22 December 2020 - Data show Darzalex in combination with bortezomib, thalidomide and dexamethasone before and after autologous stem cell transplant ...
Posted by Michael Wonder on 21 Dec 2020
Health Canada approves expanded indication for Soliqua
18 December 2020 - New indication for Soliqua offers an alternative approach for Canadians living with type 2 diabetes requiring treatment ...
Posted by Michael Wonder on 18 Dec 2020
Sandoz Canada receives authorisation from Health Canada to launch new biosimilar Hyrimoz (adalimumab)
17 December 2020 - Hyrimoz approved for use in all same indications as reference medicine* including rheumatology, gastro-enterology and dermatology. ...
Posted by Michael Wonder on 16 Dec 2020
Health Canada approves Venclexta (venetoclax) in combination with azacitidine or low dose cytarabine for untreated acute myeloid leukaemia
15 December 2020 - Health Canada's approval of Venclexta for newly diagnosed AML patients who are ineligible for intensive chemotherapy is ...
Posted by Michael Wonder on 10 Dec 2020
Valeo Pharma announces Health Canada approval for Redesca and Redesca Hp
9 December 2020 - Valeo Pharma announced today that Health Canada has issued a Notice of Compliance for Redesca and ...
Posted by Michael Wonder on 02 Dec 2020
Health Canada licenses Xeomin (incobotulinumtoxinA) for adult patients with sialorrhea
1 December 2020 - Merz Therapeutics today announced Health Canada’s notice of compliance for Xeomin (incobotulinumtoxinA) for the treatment of chronic ...
Posted by Michael Wonder on 26 Nov 2020
Lynparza (olaparib) receives Health Canada approval for the treatment of BRCA or ATM gene-mutated metastatic castration-resistant prostate cancer
25 November 2020 - On 21 August 2020, Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious ...
Posted by Michael Wonder on 24 Nov 2020
Lilly and the Government of Canada sign an agreement for the supply of bamlanivimab to treat COVID-19 in Canada
24 November 2020 - Bamlanivimab is a SARS-CoV-2-neutralising antibody that emerged from the collaboration between Lilly and Vancouver-based AbCellera. ...
Posted by Michael Wonder on 24 Nov 2020
Rigel and Medison announce Health Canada approval of Tavalisse, an oral medication for the treatment of adults with chronic immune thrombocytopenia
23 November 2020 - Rigel Pharmaceuticals and Medison Pharma today announced that Health Canada has approved the new drug submission ...
Posted by Michael Wonder on 20 Nov 2020
Lilly's neutralising antibody bamlanivimab (LY-CoV555) receives interim authorisation from Health Canada as a treatment for COVID-19
20 November 2020 - Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera. ...
Posted by Michael Wonder on 18 Nov 2020
Knight Therapeutics announces filing of supplement to a new drug submission for Nerlynx (neratinib) to treat HER2-positive metastatic breast cancer
3 September 2020 - Knight Therapeutics Inc. announced filing of the supplement to a new drug submission (SNDS) of Nerlynx ...
Posted by Michael Wonder on 18 Nov 2020
HLS Therapeutics announces Health Canada approval of Perseris for the treatment of schizophrenia
17 November 2020 - First once-monthly risperidone long-acting injectable used in the treatment of schizophrenia. ...